Amylyx Pharmaceuticals (AMLX) Gross Profit (2022 - 2024)

Amylyx Pharmaceuticals has reported Gross Profit for 3 years, with the latest figure at -$636000.0 in Q4 2024.

• On a quarterly basis, Gross Profit fell 100.64% year-over-year to -$636000.0 in Q4 2024; TTM through Sep 2025 was -$636000.0, a 100.35% decrease from a year earlier, with the FY2024 full-year figure at $81.4 million, down 77.08% from the prior year.
• Gross Profit was -$636000.0 for Q4 2024 at Amylyx Pharmaceuticals, down from $416000.0 in the prior quarter.
• The five-year high for Gross Profit was $99.1 million in Q4 2023, with the low at -$636000.0 in Q4 2024.
• Average Gross Profit over 3 years is $45.8 million, with a median of $42.6 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Gross Profit jumped 56243.93% in 2023, then tumbled 100.64% in 2024.
• Over 3 years, Gross Profit stood at $19.1 million in 2022, then jumped by 419.77% to $99.1 million in 2023, then sank by 100.64% to -$636000.0 in 2024.
• The last three Gross Profit figures came in at -$636000.0 (Q4 2024), $416000.0 (Q3 2024), and $1.0 million (Q2 2024), per Business Quant data.